The USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI)
H1 FY23 revenues at Rs. 860.1 crore, higher by 40% YoY whereas PAT at Rs. 52.6 crore, higher by 4% YoY
Indigenously-developed molecular diagnostics have helped expand the reach of diagnosis to every part of the country today
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Ensitrelvir is being evaluated for the treatment of COVID-19 to be administered as an oral tablet formulation taken once daily for five days.
Department and Industry Associations to organize 3 days National Level Expo on Indian Medical Devices Sector at Pragati Maidan, New Delhi between 9-11 Dec 2022, first of its kind expo in India
Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.
Subscribe To Our Newsletter & Stay Updated